OQS
NBIX icon

Occudo Quantitative Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Occudo Quantitative Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,175
Closed -$1.51M – 1223
2022
Q3 		$1.51M Buy
+14,175
New +$1.44M 0.12% 259

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Occudo Quantitative Strategies's NBIX Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 14,175 shares — an estimated $1.51M sold.

Occudo Quantitative Strategies first reported a position in NBIX in Q3 2022 and held it in 1 quarter. The position peaked at $1.51M in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 14,175 Neurocrine Biosciences shares in Q4 2022, an estimated $1.51M.
  • Occudo Quantitative Strategies first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 1 quarter.
  • Occudo Quantitative Strategies's Neurocrine Biosciences position peaked at $1.51M in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.